Phylogica and Isogenica: Strategic alliance fast tracking screening of drug discovery targets

24-Feb-2011 - Australia

Phylogica Ltd  and Isogenica Ltd have succeeded in a proof of concept project demonstrating compatibility of Isogenica’s proprietary CIS in-vitro display technology for peptide engineering and drug discovery with Phylogica’s Phylomer drug discovery platform.

Phylogica scientists are now confident that using the display technology will ensure accelerated screening of the company’s vast Phylomer libraries to meet demand from potential pharmaceutical partners. Isogenica has been successful in hitting all milestones to date related to the collaboration, which was announced in January 2010.

The objectives of the project were to use Isogenica’s CIS display to achieve further optimisation of Phylogica’s lead compounds targeting CD40 ligand (CD40L).

Other news from the department business & finance

More news from our other portals

All FT-IR spectrometer manufacturers at a glance